

REGISTERED COMPANY NUMBER: 07955451 (England and Wales)
REGISTERED CHARITY NUMBER: 1147457

Report of the Trustees and
Financial Statements for the Year Ended 31 December 2022
for
THE HPV AND ANAL CANCER FOUNDATION
LIMITED

Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Contents of the Financial Statements
for the Year Ended 31 December 2022**

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 14
Independent Examiner's Report	15
Statement of Financial Activities	16
Balance Sheet	17
Notes to the Financial Statements	18 to 26
Detailed Statement of Financial Activities	27 to 28

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Reference and Administrative Details
for the Year Ended 31 December 2022**

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	128 City Road London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St. John's Lane London EC1M 4BS
BANKERS	HSBC 455 Strand London WC2R 0RH

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2022

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 26. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given an overview of the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

Risk Management

The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and are satisfied that systems are in place to mitigate those risks which the charity may face.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organisation. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2022 was £154,892 and expenditure was £173,009.

Reserves Policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2022

OBJECTIVES AND ACTIVITIES

Objectives and aims

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

KEY ACHIEVEMENTS IN 2021

NOMAN is an Island

The NOMAN is an Island Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination, while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMAN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona - Ibiza: Row to End HPV, over 150 individuals - and their hundreds of supporters - have embraced the cause and our values. These NOMAN have raised awareness about HPV-cancers on a local, national, and international scale as well as funds to support our programmes.

The passion of our participants never ceases to amaze us, especially in the context of the COVID-19 pandemic. The NOMAN Campaign implemented the necessary parameters and covid regulations to enable our scheduled endurance and awareness events to take place.

2022 saw NOMAN riders take on Haute Route events at Alpe D'Huez and Davos. The Haute Route is the world's most prestigious cycling event for amateur cyclists. The races provide unparalleled experiences with 3- or 7-day professional road cycling events in the most iconic cycling destinations worldwide. During the 3-day events, riders take on some 300km and 8000m+ of vertical ascent, testing themselves against the most infamous climbs in the world, all in the name of raising awareness of HPV-related cancers. Additionally, at each event all participants were given our END HPV socks to light up the climbs and generate conversation about our work to eliminate HPV cancers. NOMAN co-founder Tristan Almada also spoke about our mission to eliminate HPV cancers at the pre-stage briefing event.

Back in the United Kingdom, NOMAN riders also took on Ride London Essex's new route, racing through the streets of the capital and the surrounding countryside. We thank all our athletes for their sacrifice and energy as NOMAN.

We look forward to 2023 and building upon our Haute Route partnership and the 10th anniversary edition of our Barcelona - Ibiza: Row to End HPV.

HPV ACTION EUROPE NETWORK

In 2018 and 2019, the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for cancer patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professionals and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community. Together with ECO, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers. In 2021, we achieved a milestone by securing for the first time a commitment to eliminate HPV cancers in Europe's Beating Cancer Plan. The HPV Action Network built on this major success with the following achievements in 2022:

Published research mapping the current state of HPV vaccination and cervical screening programmes across the European region

OBJECTIVES AND ACTIVITIES

Through this mapping exercise, we have been able to identify nations that are actively addressing HPV-induced cancers and, more crucially, those that are lagging behind. In various countries across the European Region, initiatives such as HPV vaccination and cervical cancer screening programs are notably absent. Even among those with vaccination efforts, a gender-neutral approach is not universally adopted. Notably, numerous countries with established vaccination and screening initiatives are encountering challenges in achieving optimal service utilisation.

There remains a substantial amount of work to be done to eliminate HPV cancers as a public health concern. Examining the state of HPV prevention across the WHO European region (WHO EURO), this data collection and analysis will inform the HPV Action Europe Network's strategy to implement change. Armed with the invaluable insights provided in this report, we are committed to expediting actions at the regional level. Additionally, we aim to lend our support to the advocacy endeavours of HPV organisations within individual countries. This collaborative approach is aimed at ensuring that all healthcare systems take the necessary steps to effectively safeguard their populations, which could lead to the prevention of nearly 100,000 cancer cases annually.

Published an 'umbrella review' of interventions used to improve HPV vaccine uptake in children, adolescents and young adults. The results were also published in the journal STI.

The HPV Action Network conducted an important review of published evidence, identifying various policies and programmes that have improved intention and uptake rates for HPV vaccination including printed materials, SMS based health information, face-to-face presentations and Q&A sessions. HPV vaccination is easy to deliver, has immediate positive health impacts, and is highly efficacious, making it one of the most effective cancer prevention strategies available. The findings of this review will be disseminated widely, with the aim of encouraging the best possible use of this evidence in HPV vaccination programmes across Europe and beyond.

HPV vaccination rates for girls in Europe and other parts of the world are highly variable, with only two European countries achieving a 90% uptake of all vaccine doses for girls. While some countries have managed to achieve over 70% uptake, others have rates below 50%, with at least two countries vaccinating fewer than 10% of girls.

The main reason for these sub-optimal vaccination rates is low vaccine confidence among parents, carers, and young people themselves. This may be due to inadequate information, distrust in health authorities and vaccine manufacturers, and concerns regarding vaccine safety. However, interventions can improve vaccine confidence and increase uptake rates.

Successfully applied for EU4Health funding for the two year PROTECT-EUROPE project which will focus on increasing HPV vaccination uptake in EU member states.

The EU4Health programme was adopted as a response to the COVID-19 pandemic and to reinforce crisis preparedness in the EU. The pandemic highlighted the fragility of national health systems. The EU4Health programme will bring a contribution to the long-term health challenges by building stronger, more resilient and more accessible health systems, through financial support from the European Union.

Through this funding, the PROTECT-EUROPE project will champion gender-neutral HPV vaccination in the EU to protect everyone against HPV cancers, by providing information and guidance to EU Member States on:

- How healthcare professionals can better communicate directly with young people and their parents or caregivers.
- How public health messaging on HPV can be tailored to better resonate with young people and their parents or caregivers.
- How other innovative approaches, such as bundling various adolescent vaccines, could improve HPV vaccine uptake.

This project will commence in January 2023.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

Other achievements for the HPV Action Network in 2022 include:

- Commissioned 'HPV Changemakers' to highlight the personal stories of individuals who have successfully made the case for change in the field of HPV cancer elimination in their own countries.
- Started work on pilot projects in Romania and Bulgaria to develop multi-organisation advocacy campaigns as part of the Action Now on HPV project.
- Responded to the WHO Europe consultation on its Roadmap for the Elimination of cervical cancer and made the case for wider action in a presentation to the WHO Europe Regional Committee meeting in September.

Future plans

In 2023 and beyond, the HPV Action Network will:

- Encourage and support the EC and EU Member States to implement Europe's Beating Cancer Plan.
- Start work on PROTECT-EUROPE.
- Make the case for action to address the impact of the pandemic on vaccination and screening programmes.
- Launch 'HPV Changemakers.'
- Launch the pilot advocacy projects in Romania and Bulgaria. The next step will be to identify other countries in the European region where a similar approach can be developed.
- Continue to support the HPV Coalition in the UK.
- Advocate for the inclusion of gender-neutral HPV vaccination in the European Code Against Cancer.

HPV Coalition

In October, the NOMAN Campaign was proud to join forces with Jo's Cervical Cancer Trust to launch and co-chair the new HPV Coalition in the United Kingdom.

The HPV Coalition is an expert advisory group of leading patient groups, professional groups, clinicians, and expert individuals who have come together to inform and advance the UK's journey towards elimination of HPV-related cancers - cancers which account for 5% of all cancers globally, and which we now, for the first time in history, have the opportunity to eliminate as a public health threat.

Despite the scale of the opportunity, the UK has yet to take the step of other countries, such as Australia and Canada, in developing an action plan for cervical cancer elimination. The UK also lags behind the European Union which, through the Beating Cancer Plan, has gone one step further, in committing to eliminate all HPV cancers. The HPV Coalition is therefore eager to see the UK put in place a concrete plan for elimination as a matter of priority, targeted at the whole range of HPV-related cancers and supporting access to preventative interventions for all parts of the population.

The Coalition will stand at the forefront of UK policymaking and will bring together a membership of patient organisations, professional groups, clinicians, and expert individuals to build and demonstrate broad stakeholder consensus around the significant - and as yet unharnessed - opportunity to pursue elimination in the UK. The membership will advocate for commitment and action from all UK governments to pursue elimination of the whole range of HPV-related cancers, in both men and women.

On October 24th 2022, the Coalition was officially launched in the Palace of Westminster in an event hosted by long standing HPV advocate, Jess Phillips MP, and supported by politicians from both sides of the aisle, as well as community stakeholders such as HPV cancer thrivers.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2022

OBJECTIVES AND ACTIVITIES

The next step for the Coalition will be the publication of a roadmap in Spring 2023 which will provide a blueprint of how the elimination of HPV cancers can be delivered in the UK. This will set out ambitious, yet realistic goals, mapping out key areas of action, including milestones, markers of success, and research recommendations for areas which require further understanding. Once published, this will be utilised to engage with policy and parliamentary stakeholders to facilitate wider consensus around the roadmap and the ultimate goal of elimination.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,500 people, and in the US, about 9,700 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer Support Program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2022, the HPVACF's Peer to Peer Support Program included 1014 thrivers, caregivers, and peer mentors.

Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 5,000 people by the end of 2022. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 10,700 times by the end of the year.

Anal Cancer Patient Conference

On October 1st, 2022, the Anal Cancer Foundation held the second Anal Cancer Patient Summit.

Medical professionals spoke about anal cancer causes, treatments, and how to mitigate the various side effects of chemoradiation. We also heard from advocates who taught us, through sharing their own stories, how to use our personal experiences to advance the fight against anal cancer. Finally, thrivers were able to network both in groups and within one-on-one sessions which, for many people, was the first time they were meeting a fellow thriver.

The conference was created to provide an annual opportunity for anal cancer patients and caregivers to learn from medical professionals, connect with experts and each other, and take action to empower themselves and this community.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2022

OBJECTIVES AND ACTIVITIES

Over 400 people registered for the conference from 20 countries around the world. Feedback from participants included: "This was beyond outstanding" and "Great Summit. Learned so much more than I thought I needed to know - Terrific!"

Anal Cancer Foundation Co-Founder Justine Almada facilitated the day's events. Experts including Drs. Joel Palefsky, Cathy Eng, and Paul Romesser spoke about anal cancer causes, treatments, emerging therapies, and quality of life after treatment. Thrivers were given the opportunity to ask questions live, as well as to connect with one another. Anal Cancer Thriver and Activist Marcia Cross shared her own story alongside several other thrivers, guiding the audience in how to use their personal experiences to advance the fight against anal cancer.

We would like to make sure every family facing anal cancer has access to the same information as their doctors. Recordings of the day's events are now available on YouTube. We will hold another Anal Cancer Patient Summit on October 21st, 2023.

NCCN Treatment Guidelines

In 2021, we were thrilled to partner with NCCN to create the first anal cancer treatment guide for patients, enabling patients and their caregivers to take charge of their own care and recovery. This year, NCCN updated the guidelines for 2022, again with input from the Anal Cancer Foundation.

The National Comprehensive Cancer Network is an alliance of 31 cancer centers in the USA, recognized for dealing with complex and/or rare cancers. NCCN Clinical Guidelines are the recognized standard for clinical direction and policy in cancer care and are among the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care-including physicians, nurses, pharmacists, payers, patients, and their families-with the ultimate goal of improving patient care and outcomes. This companion guide for patients is the next step forward in empowering patients with accessible information.

We hope this anal cancer treatment guide presents clinical information in an easy-to-read format for people with cancer and those who support them. The patient guideline is intended to:

- Equip patients and providers with the same information as that of their medical team
- Ensure that patients, no matter where they are treated, know what the experts agree upon as the standard of treatment and care
- Empower patients with knowledge about all of their treatment and care choices
- Allow patients to self-advocate for their own best care

ANCHOR Study

A ground-breaking randomised controlled national trial of 4,500+ people has shown that anal cancer can be prevented by routine screening and removal of precancerous cells. The ANCHOR Study hoped to improve patient outcomes for people with anal precancer and cancer by finding the best way to stop anal precancer from progressing to cancer. The Anal Cancer Foundation built and led the coalition of organizations that supported and pushed for the study.

ANCHOR stands for Anal Cancer HSIL Outcomes Research and the study investigated treating anal cancer precursor lesions to see if this reduced the cancer risk for people living with HIV. Conceived and led by Anal Cancer Foundation Scientific Advisory Board Member Dr. Joel Palefsky, ANCHOR aimed to recruit 5,000 people living with HIV and was randomized into two groups: treatment of anal precancer and a control group.

What was ANCHOR researching?

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2022

OBJECTIVES AND ACTIVITIES

Prevention and early detection are essential to ending anal cancer. Yet, despite its growing incidence and mortality, there are no national screening guidelines for anal cancer or precancer. The rates of cervical cancer reduced by 80% once doctors starting screening for and treating cervical precancer.

The hope was that the ANCHOR study would illustrate that treating anal precancer will reduce the risk of anal cancer. The ANCHOR study had two main objectives: to determine the effectiveness of screening for and treating anal precancer, to reduce the incidence of anal cancer in HIV-positive men and women, and to create a bank of blood, anal swab, and tissue specimens to support critical scientific studies on how anal cancer progresses. There were two arms in the study: one arm that received treatment for anal precancer and a control arm that did not.

Ninety percent of anal cancer is caused by the human papillomavirus (HPV), which can cause changes to the skin around and inside the anus. These changes are called "high-grade squamous intraepithelial lesions" or HSIL. Not all anal HSIL will develop into cancer. Most HSIL will go away on their own, but some become cancer over time and can eventually spread to other parts of the body. The incidence of anal cancer is highest in people living with HIV.

What were the outcomes?

Results were published in The New England Journal of Medicine in June of 2022. They demonstrated that this reduction was as high as 57%, achieved through routine screening and removal of precancerous cells.

Additional findings include:

- A higher prevalence of HSIL than anticipated. This was most surprising in women. They were expecting 10% prevalence but found 47.2%.
- The study diagnosed 17 people with cancer, which was higher than expected.
- There was a younger median age at diagnosis than expected.
- There was no real difference in age, race, or gender in those who progressed to cancer, but a large difference in cancer progression in smokers as compared to non-smokers.

Expert Hour Webinar Series

When you know what your providers know, you are empowered to have more in-depth and productive conversations toward our #1 priority: getting you the best care possible.

We bring the experts right to our community and held our inaugural Expert Hour webinar series: Clinical Trials 101 and Immunotherapy 101, featuring world-renowned experts and a live Q&A with Dr. Lee Rosen of the University of California, Los Angeles, and Dr. Julius Strauss of the National Institutes of Health holding informative and insightful sessions. We were thrilled at the quality and depth of information about anal cancer they each brought directly to the community.

Clinical Trials 101

March 18: Clinical Trials 101: Dr. Rosen guided us through myths and facts about clinical trials, provided questions to ask when considering a trial, and outlined how to frame clinical trials during the treatment journey.

Immunotherapy 101

April 21: Immunotherapy 101: Dr. Strauss presented on the types of immunotherapies and how they work, what factors affect response to immunotherapy, potential side effects, and how to access immunotherapy clinical trials.

Thank you to our experts and to our participants!

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.
- Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

On June 5th, the third day of the 2022 IANS Scientific Meeting in New York, a panel of brave and outspoken thrivers and advocates shared their experiences with the assembled medical experts, in a session entitled, "Rare and Misunderstood: Ten Years Later - Narratives and Perspective on the Anal Cancer Experience." The session was led and facilitated by Patient Advocate at IANS, Mary-Jo Murphy.

Invited speaker Justine Almada put forward the Foundation's vision for ending the disease and called on everyone gathered to join together and RAISE their game.

Her call for RAISE means that we, collectively:

Refer to comprehensive care, both during and after treatment
Advocate for screening
Invest in research for new treatments
Stop the Stigma with connection and community
Ensure early and accurate diagnosis

Daun, Steven, Stephen and John gave testimony of their journeys. These were raw and honest first-person stories from people who have been through the isolating, confusing, and painful experience of anal cancer and precancer. They gave no-holds-barred details on what had happened to them and how their lives had been changed by anal cancer and precancer.

The road ahead in anal cancer prevention and treatment improvement is long, but the scientific meeting and patient panel made it clear that no one is in this alone.

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our Living with Anal Cancer section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients' stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer Support Program.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2022

OBJECTIVES AND ACTIVITIES

Our goal in 2022 continued to be ensuring that more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources.

With the pandemic reducing the in-person resources available to the anal cancer community, the need for communication was more important than ever. Our communications strategy focused on consistency and "useful" information, with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

ACF's 2022 direct impact includes:

- 130+ new anal cancer thrivers and caregivers signing up to be matched through the Peer to Peer Support Program.
- 250+ anal cancer thrivers and caregivers helped by the 1:1 Patient Navigation Service. Peer to Peer Support signups are up 28% on 2020 figures.
- 25 thrivers sharing their story publicly with our community through our Share Your Story Initiative.
- 650+ people participating in our informational forums.

Overall, in 2022, ACF directly served over 1,100 anal cancer patients through our best-in-class patient programs, at no cost to them, interest in our resources increased with web session duration up 17% over 2021, and countless people will benefit from our advocacy, this year and for several years to come.

Going forward, we will continue working to provide all the support the anal cancer community needs.

LOOKING AHEAD: 2023

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eliminate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

The UK began vaccinating boys against HPV in September 2019 and we will continue to work with stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12-13-year-old boys is as high as possible. The work of the HPV Coalition will be important in ensuring the unprecedented opportunity to eliminate HPV cancers in the United Kingdom is not missed on the back of the interruption caused by the pandemic.

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent, continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer. By continuing to build our evidence base, seek and identify barriers to uptake in EC member countries, and launch advocacy groups in member states, we are confident that more countries will sign up to gender neutral protection initiatives.

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. Our flagship Barcelona - Ibiza: Row to End HPV event will hold its 10-year anniversary, serving as an opportunity to galvanise both long-standing and new supporters and furthering the reach of our message to prevent 5% of cancer. With the NOMAN side of the organisation leading on HPV-related activities, we will continue to partner with the Haute Route on further cycling events as their European Charity Partner, and continue to educate about our ability to end HPV cancers.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2022

OBJECTIVES AND ACTIVITIES

We will continue to push for legislative, research and policy changes to end anal cancer and improve the lives of those affected by it. We are excited by the response to our Patient Summit and "Ask the Expert" sessions and look forward to providing more touchpoints for our community with these and the patient conference in 2023. Our Peer to Peer support program retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Public benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

FINANCIAL REVIEW

Reserves policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

Going concern

As stated in note 19, the Trustees have considered the effect of the current economic climate. The Trustees consider that the current economic climate is likely to cause disruption to the Charity's activities but are confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twelve months from the date of approval of these financial statements as well as for the foreseeable future.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document, structure and management

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charity on the 25 May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The Trustees are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 18. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws and policies.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and systems are in place to mitigate those risks which the charity may face.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on27.09.2023..... and signed on its behalf by:



.....
T Almada - Trustee

**Independent Examiner's Report to the Trustees of
The HPV and Anal Cancer Foundation
Limited**

Independent examiner's report to the trustees of The HPV and Anal Cancer Foundation Limited ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst

Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

Date: 28/09/2023

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Statement of Financial Activities
(Incorporating an Income and Expenditure Account)
for the Year Ended 31 December 2022**

	Notes	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		90,094	-	90,094	2,083
Other trading activities	2	64,776	-	64,776	202,664
Investment income	3	22	-	22	2
Total		154,892	-	154,892	204,749
EXPENDITURE ON					
Raising funds	4	16,407	-	16,407	56,981
Charitable activities	5				
Care and Support		47,957	-	47,957	47,743
Awareness Raising & Education		103,849	-	103,849	146,825
Research for a Cure		4,796	-	4,796	4,325
Total		173,009	-	173,009	255,874
NET INCOME/(EXPENDITURE)		(18,117)	-	(18,117)	(51,125)
RECONCILIATION OF FUNDS					
Total funds brought forward		62,964	13,100	76,064	127,189
TOTAL FUNDS CARRIED FORWARD		44,847	13,100	57,947	76,064

The notes form part of these financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED (REGISTERED NUMBER: 07955451)**

**Balance Sheet
31 December 2022**

	Notes	2022 £	2021 £
CURRENT ASSETS			
Debtors	14	831	327
Cash at bank		67,779	83,806
		68,610	84,133
CREDITORS			
Amounts falling due within one year	15	(10,663)	(8,069)
NET CURRENT ASSETS		57,947	76,064
TOTAL ASSETS LESS CURRENT LIABILITIES		57,947	76,064
NET ASSETS		57,947	76,064
FUNDS	17		
Unrestricted funds		44,847	62,964
Restricted funds		13,100	13,100
TOTAL FUNDS		57,947	76,064

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2022.


The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on**27.09.2023**..... and were signed on its behalf by:


.....
T Almada - Trustee

Type text here

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial reporting standard 102 - reduced disclosure exemptions

The charitable company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories - over 3 years

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

1. ACCOUNTING POLICIES - continued

Fund accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgments and key sources of estimation uncertainty

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have a significant effect on amounts recognised in the financial statements.

2. OTHER TRADING ACTIVITIES

	2022	2021
	£	£
Fundraising events	64,776	202,664

3. INVESTMENT INCOME

	2022	2021
	£	£
Deposit account interest	22	2

4. RAISING FUNDS

Raising donations and legacies

	2022	2021
	£	£
Staff costs	6,585	5,900
Development expenses	42	118
Donor software subscription	2,167	2,002
Event Expenses	4,626	46,842
Support costs (Operating)	2,987	2,119
	16,407	56,981

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 6) £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Care and Support	31,802	-	16,155	47,957
Awareness Raising & Education	65,467	17,069	21,313	103,849
Research for a Cure	3,092	-	1,704	4,796
	100,361	17,069	39,172	156,602

6. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2022 £	2021 £
Staff costs	37,310	33,429
Development Expenses	3,032	5,035
Marketing	34,297	43,064
Miscellaneous Expense	2,104	1,682
Event Expenses	4,626	46,843
Media	17,552	20,778
Internet and Website	1,440	-
	100,361	150,831

7. GRANTS PAYABLE

	2022 £	2021 £
Awareness Raising & Education	17,069	17,365
The total grants paid to institutions during the year was as follows:		
	2022 £	2021 £
European Cancer Organisation	17,069	17,365

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

8. SUPPORT COSTS

	Finance £	Other £	Governance costs £	Totals £
Raising donations and legacies	62	2,016	909	2,987
Care and Support	107	14,472	1,576	16,155
Awareness Raising & Education	213	17,949	3,151	21,313
Research for a Cure	28	1,252	424	1,704
	<u>410</u>	<u>35,689</u>	<u>6,060</u>	<u>42,159</u>

Support costs, included in the above, are as follows:

	Raising donations and legacies £	Care and Support £	Awareness Raising & Education £
Bank charges	62	107	213
Pensions	747	1,296	2,592
Rent and Rates	859	1,488	2,976
Insurance	41	72	144
Fees and subscriptions	-	303	303
Telephone, printing, postage and stationery	21	133	169
Sundries	-	-	-
Travel and Meetings	-	322	323
Staff Training	26	-	26
Consultancy fees	-	10,300	10,300
Conference expenses	322	558	1,116
Independent Examiner's fee	765	1,326	2,652
Accountancy and legal fees	144	250	499
	<u>2,987</u>	<u>16,155</u>	<u>21,313</u>
		2022	2021
	Research for a Cure £	Total activities £	Total activities £
Bank charges	28	410	274
Pensions	349	4,984	4,884
Rent and Rates	401	5,724	3,680
Insurance	19	276	480
Fees and subscriptions	-	606	714
Telephone, printing, postage and stationery	10	333	563
Sundries	-	-	519
Travel and Meetings	323	968	1,620
Staff Training	-	52	67
Consultancy fees	-	20,600	16,229
	<u>1,130</u>	<u>33,953</u>	<u>29,030</u>
Carried forward			

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

8. SUPPORT COSTS - continued

		2022	2021
	Research for a Cure £	Total activities £	Total activities £
Brought forward	1,130	33,953	29,030
Conference expenses	150	2,146	606
Independent Examiner's fee	357	5,100	3,180
Accountancy and legal fees	67	960	-
	1,704	42,159	32,816

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2022	2021
	£	£
Independent Examiner's fee	5,100	3,180

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2022 nor for the year ended 31 December 2021.

11. STAFF COSTS

	2022	2021
	£	£
Wages and salaries	34,140	39,329
Social security costs	9,755	-
Other pension costs	4,984	4,884
	48,879	44,213

The average monthly number of employees during the year was as follows:

	2022	2021
	1	1

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £49,194 (2021: £44,213).

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	2,083	-	2,083
Other trading activities	202,664	-	202,664
Investment income	2	-	2
Total	204,749	-	204,749
EXPENDITURE ON			
Raising funds	56,981	-	56,981
Charitable activities			
Care and Support	47,743	-	47,743
Awareness Raising & Education	146,825	-	146,825
Research for a Cure	4,325	-	4,325
Total	255,874	-	255,874
NET INCOME/(EXPENDITURE)	(51,125)	-	(51,125)
RECONCILIATION OF FUNDS			
Total funds brought forward	114,089	13,100	127,189
TOTAL FUNDS CARRIED FORWARD	62,964	13,100	76,064

13. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1 January 2022 and 31 December 2022	47,250
DEPRECIATION	
At 1 January 2022 and 31 December 2022	47,250
NET BOOK VALUE	
At 31 December 2022	-
At 31 December 2021	-

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Gift aid recoverable	831	327
	<u><u> </u></u>	<u><u> </u></u>

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Social security and other taxes	-	4,889
Deferred income	5,922	-
Accrued expenses	4,741	3,180
	<u><u>10,663</u></u>	<u><u>8,069</u></u>

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds	Restricted funds	2022 Total funds	2021 Total funds
	£	£	£	£
Current assets	55,510	13,100	68,610	84,133
Current liabilities	(10,663)	-	(10,663)	(8,069)
	<u><u>44,847</u></u>	<u><u>13,100</u></u>	<u><u>57,947</u></u>	<u><u>76,064</u></u>

17. MOVEMENT IN FUNDS

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	62,964	(18,117)	44,847
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u><u>76,064</u></u>	<u><u>(18,117)</u></u>	<u><u>57,947</u></u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	154,892	(173,009)	(18,117)
TOTAL FUNDS	<u><u>154,892</u></u>	<u><u>(173,009)</u></u>	<u><u>(18,117)</u></u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

17. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	114,089	(51,125)	62,964
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u>127,189</u>	<u>(51,125)</u>	<u>76,064</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	204,749	(255,874)	(51,125)
TOTAL FUNDS	<u>204,749</u>	<u>(255,874)</u>	<u>(51,125)</u>

Capital fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2022.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

19. GOING CONCERN

The Trustees have considered the effect of the current economic climate on the Charity's activities. The Charity currently holds a comfortable level of reserves and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2022**

	2022 £	2021 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	4,936	2,083
Grants	85,158	-
	<u>90,094</u>	<u>2,083</u>
Other trading activities		
Fundraising events	64,776	202,664
Investment income		
Deposit account interest	22	2
	<u>154,892</u>	<u>204,749</u>
Total incoming resources		
EXPENDITURE		
Raising donations and legacies		
Wages	6,585	5,900
Development expenses	42	118
Donor software subscription	2,167	2,002
Event Expenses	4,626	46,842
	<u>13,420</u>	<u>54,862</u>
Charitable activities		
Wages	27,555	33,429
Social security	9,755	-
Development Expenses	3,032	5,035
Marketing	34,297	43,064
Miscellaneous Expense	2,104	1,682
Event Expenses	4,626	46,843
Media	17,552	20,778
Internet and Website	1,440	-
Grants to institutions	17,069	17,365
	<u>117,430</u>	<u>168,196</u>
Support costs (Operating)		
Finance		
Bank charges	410	274
Other		
Pensions	4,984	4,884
Carried forward	4,984	4,884

This page does not form part of the statutory financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2022**

	2022 £	2021 £
Other		
Brought forward	4,984	4,884
Rent and Rates	5,724	3,680
Insurance	276	480
Fees and subscriptions	606	714
Telephone, printing, postage and stationery	333	563
Sundries	-	519
Travel and Meetings	968	1,620
Staff Training	52	67
Consultancy fees	20,600	16,229
Conference expenses	2,146	606
	<u>35,689</u>	<u>29,362</u>
Governance costs		
Independent Examiner's fee	5,100	3,180
Accountancy and legal fees	960	-
	<u>6,060</u>	<u>3,180</u>
Total resources expended	<u>173,009</u>	<u>255,874</u>
Net expenditure	<u>(18,117)</u>	<u>(51,125)</u>

This page does not form part of the statutory financial statements